SNDX · XBRL financial data

Syndax Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (SNDX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	2	140	0	0	24	172
Research and development	50	88	118	163	242	259
Selling, general and administrative	—	25	33	67	121	180
General and administrative	23	25	33	—	—	—
Total operating expenses	73	113	152	230	363	445
Operating income (loss)	(71)	26	(152)	(230)	(340)	(273)
Interest income	1	0	6	21	26	23
Interest expense	2	2	3	0	5	0
Other income (expense)	(0)	0	(0)	(0)	(0)	(1)
Income tax expense (benefit)	0	0	—	—	—	0
Net income (loss)	(73)	25	(149)	(209)	(319)	(285)
Earnings per share, basic USD per share	(1.87)	0.48	(2.46)	(2.98)	(3.72)	(3.29)
Earnings per share, diluted USD per share	(1.87)	0.46	(2.46)	(2.98)	(3.72)	(3.29)
Weighted average shares, basic millions of shares	41	52	61	70	86	87
Weighted average shares, diluted millions of shares	41	54	61	70	86	87

† Share count changed about 1/804 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1241x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (SNDX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	115	222	74	295	154	135
Short-term investments	178	218	401	275	419	259
Accounts receivable	—	—	—	0	8	38
Inventory	—	—	—	0	0	33
Prepaid and other current assets	6	8	2	3	9	13
Total current assets	299	448	490	581	603	528
Property and equipment, net	0	0	0	0	0	0
Right-of-use asset	0	1	1	1	2	1
Total assets	301	450	497	613	725	530
Accounts payable	4	6	4	10	12	17
Current portion of long-term debt	—	—	—	0	338	350
Total current liabilities	19	21	29	58	104	120
Lease liability, non-current	0	1	1	1	2	—
Total liabilities	48	41	30	59	437	465
Accumulated deficit	(569)	(544)	(693)	(902)	(1,221)	(1,507)
Total stockholders' equity	252	408	467	554	288	65
Total liabilities and equity	301	450	497	613	725	530
Common shares outstanding (cover page) millions of shares	48	55	0	85	86	88

† Share count changed about 1/804 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1241x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (SNDX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(73)	25	(149)	(209)	(319)	(285)
Stock-based compensation	9	13	16	31	43	48
Net cash from operating activities	(71)	29	(134)	(161)	(275)	(323)
Purchases of property and equipment	0	0	0	0	0	0
Net cash from investing activities	(143)	(41)	(186)	118	(220)	290
Net cash from financing activities	304	118	172	264	353	14
Net change in cash	91	107	(148)	221	(141)	(19)

† Share count changed about 1/804 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1241x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Syndax Pharmaceuticals	136	83	(27)*	not reported	11.9 quarters	Q3 FY26 10-QSep 30, 2026
Nurix Therapeutics	720	673	616*	109.2M	—	Q3 FY26 10-QAug 31, 2026
Niagen Bioscience	70	27	not reported	79.2M	—	Q3 FY26 10-QSep 30, 2026
Cogent Biosciences	181	not reported	(77)*	173.5M	10.3 quarters	Q2 FY26 10-QJun 30, 2026
uniQure	98	5.2	(48)*	70.1M	2.6 quarters	Q3 FY26 10-QSep 30, 2026
Phibro Animal Health	76	387	26	not reported	—	Q1 FY27 10-QSep 30, 2026
Pacira BioSciences	206	192	57*	39.9M	—	Q2 FY26 10-QJun 30, 2026
Wave Life Sciences	197	13	(60)*	197.2M	7.4 quarters	Q3 FY26 10-QSep 30, 2026
Avadel Pharmaceuticals	80	77	22*	97.7M	—	Q3 FY25 10-QSep 30, 2025

Not investment advice. Not affiliated with the U.S. SEC.